Philip Morris International Inc.

Philip Morris International Inc.

PM

$211.28

Updated: 05/11/2026, 01:06:19

Market Cap
$329.30B
Sector
Consumer Defensive
Industry
Tobacco
Country
US

No historical data available

Company Profile

Philip Morris International Inc. functions as a prominent tobacco enterprise, actively working toward a smoke-free future. The company is strategically diversifying its long-term product range to incorporate items beyond traditional tobacco and nicotine. Its primary business involves both conventional cigarettes and an expanding array of smoke-free alternatives, such as innovative heat-not-burn devices, vapor products, and oral nicotine solutions. These offerings are distributed in markets worldwide, with the exception of the United States. The smoke-free portfolio includes brands like HEETS (encompassing Creations, Dimensions, Marlboro variants), Parliament HeatSticks, and TEREA, in addition to KT&G-licensed brands Fiit and Miix. For conventional cigarettes, the company sells internationally recognized brands such as Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris. Regionally, it also owns major cigarette brands like Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia, and Fortune and Jackpot in the Philippines. PMI's smoke-free innovations are currently available across 71 global markets. Established in 1987, Philip Morris International Inc. is headquartered in New York, New York.

USD
NYSE
CEO: Jacek Olczak
Employees: 84,900
https://www.pmi.com
Asset Summaries
Latest generated summaries for PM

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
PM-10-k-fy2025.html3.8 MBtext/htmlENFiled 06/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 65 KPI observations

Revenue

$40.6B

FY 2025 · Reported

Net income

$11.3B

FY 2025 · Reported

Gross margin

67.1%

FY 2025 · Calculated

Free cash flow

$10.7B

FY 2025 · Calculated

R&D intensity

1.9%

FY 2025 · Calculated

Share repurchases

N/A

FY — · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Cigarette brand portfolio and volume concentration
Smoke-free product footprint
FDA authorizations

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

PMI is a leading international consumer goods company with cigarettes and smoke-free products (IQOS, ZYN, VEEV); >$16B invested in smoke-free since 2008

98%
Source evidence
“Since 2008, we have invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke”

Company description

Smoke-free transformation: IQOS, ZYN, VEEV; $16B+ invested since 2008; goal of ending cigarette sales

98%
Source evidence
“We are a leading international consumer goods company, actively delivering a smoke-free future. ... Since 2008, we have invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products”

Primary performance obligation

Revenue recognized as performance obligations satisfied, typically upon shipment/delivery of cigarettes and smoke-free products including heat-not-burn, e-vapor and oral nicotine products

95%
Source evidence
“Our primary performance obligation is the distribution and sales of cigarettes and smoke-free products, including heat-not-burn, e-vapor and oral nicotine products.”

Four geographic segments as of December 31, 2025

Four geographic segments: Europe, SSEA/CIS/MEA, EA/AU/PMI GTR, Americas

98%
Source evidence
“As of December 31, 2025, our four geographical segments were as follows:”

Segment reorganization effective January 1, 2026

Effective January 1, 2026, segments replaced by International Smoke-Free, International Combustibles, and U.S.

97%
Source evidence
“The four geographic segments have been replaced with three new reportable segments: International Smoke-Free, International Combustibles, and U.S.”

Four geographical segments as of December 31, 2025

Europe; SSEA, CIS & MEA; EA, AU & PMI GTR; Americas — realigned in 2026 to International Smoke-Free, International Combustibles, U.S.

97%
Source evidence
“As of December 31, 2025, our four geographical segments were as follows: •Europe Region, including our Wellness business; •South and Southeast Asia, Commonwealth of Independent States, Middle East and Africa Region ("SSEA, CIS & MEA"); •East Asia, Australia, and PMI Global Travel Retail ("EA, AU & PMI GTR"); and •Americas Region.”

Distribution and sales channels

Six distribution types including direct-to-retail, distributors, wholesalers, e-commerce and own brand retail

95%
Source evidence
“Our main types of distribution and sales are tailored to the characteristics of each market and are often used simultaneously”

Cigarette brand portfolio and volume concentration

Marlboro ~43% of 2025 cigarette shipment volume; top 5 international brands 81%; sold in ~170 markets

98%
Source evidence
“led by Marlboro, the world’s best-selling international cigarette, which accounted for approximately 43% of our total 2025 cigarette shipment volume”

Smoke-free product footprint

SFPs available in 106 markets; modern oral pouches in 56 markets as of December 31, 2025

97%
Source evidence
“As of December 31, 2025, our smoke-free products were available for sale in 106 markets. With regard to modern oral pouches, we increased our presence to 56 markets.”

FDA authorizations

FDA authorized General snus, ZYN pouches and IQOS versions; first-ever MRTP authorizations for IQOS and General snus

95%
Source evidence
“Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product ("MRTP") authorizations from the FDA.”

FY2025 net revenues

$40.6 billion net revenues in FY2025, +7.3% (+6.5% ex-currency/acquisitions)

98%
Source evidence
“Net revenues of $40.6 billion for the year ended December 31, 2025, increased by $2.8 billion, or 7.3%, from the comparable 2024 amount.”

Operations and dependencies

Russia operations assets

Russian operations: ~$4.8 billion total assets (excluding intercompany), ~$2.3 billion cash mostly in rubles as of Dec 31, 2025

95%
Source evidence
“As of December 31, 2025, our Russian operations had approximately $4.8 billion in total assets, excluding intercompany balances, of which approximately $2.3 billion consisted of cash and cash equivalents held mostly in local currency (Russian rubles).”

Cash holdings including Russia concentration

Cash & equivalents $4.9B (2025) / $4.2B (2024), majority at foreign subsidiaries including $2.3B / $1.0B in Russia

95%
Source evidence
“we had cash and cash equivalent of $4.9 billion and $4.2 billion, respectively, the majority of which was held by our foreign subsidiaries, including $2.3 billion and $1.0 billion, respectively, held in Russia.”

Positioning and strategy

Swedish Match acquisition and IQOS US rights reacquisition

Swedish Match (Nov 2022) created global smoke-free combination of IQOS and ZYN; full IQOS U.S. rights from Altria effective April 30, 2024

96%
Source evidence
“In November 2022, we acquired Swedish Match AB ("Swedish Match") – a leader in oral nicotine delivery – creating a global smoke-free combination led by the companies' IQOS and ZYN brands. As of April 30, 2024, we hold the full rights to commercialize IQOS in the U.S.”

Capex focused on smoke-free manufacturing capacity

Capex $1.6B in 2025, $1.4B in 2024, primarily smoke-free product manufacturing capacity; 2026 expected $1.4-$1.6B

95%
Source evidence
“Our capital expenditures were $1.6 billion in 2025 and $1.4 billion in 2024. The 2025 capital expenditures were primarily related to our ongoing investments in smoke-free product manufacturing capacity.”

Named competitors

Competitors include Altria, BAT, Japan Tobacco, Imperial Brands, and state-owned enterprises in Algeria, Egypt, China, Taiwan, Thailand, Vietnam

96%
Source evidence
“Competitors in our industry include Altria Group, Inc., British American Tobacco plc, Japan Tobacco Inc., Imperial Brands plc”

Vectura sale and Wellness strategy

Vectura sold Dec 31, 2024 ($199M pre-tax loss); Wellness unit Aspeya pursuing cannabinoid wellness, negligible revenue expected

92%
Source evidence
“On December 31, 2024, we completed the sale. The sale resulted in a pre-tax loss of $199 m”

Market share positions

Market share of at least 15% in approximately 100 markets; #1 or #2 cigarette share in many markets

96%
Source evidence
“We have a market share of at least 15% in approximately 100 markets”

R&D concentrated on smoke-free portfolio

Smoke-free portfolio accounted for ~100% of total R&D expense in 2025 and 2024, ~99% in 2023

95%
Source evidence
“The research and development expense for our smoke-free portfolio accounted for approximately 100% of our total research and development expense for the years ended December 31, 2025 and 2024, and approximately 99% for the year ended December 31, 2023.”

Exclusive worldwide KT&G smoke-free collaboration

Long-term collaboration with KT&G to commercialize its smoke-free devices and consumables exclusively worldwide (excluding South Korea) through January 29, 2038

95%
Source evidence
“to continue to commercialize KT&G's innovative smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea). The agreement covers fifteen years, to January 29, 2038”

Risks, financing, and outlook

Disputed German heated tobacco tax surcharge payment

PMI paid ~$0.8B disputed supplemental tax surcharge on heated tobacco products in Germany in January 2025 to avoid interest accrual

95%
Source evidence
“Excise tax payments included the disputed supplemental tax surcharge on heated tobacco products in Germany of approximately $0.8 billion as PMI elected to pay the supplemental tax surcharge in January 2025 to avoid the future addition of interest”

Total debt and credit ratings

Total debt $48.8B (2025) vs $45.7B (2024), primarily fixed rate, ~7-year weighted-average maturity; ratings Moody's A2, S&P A- (Positive), Fitch A

95%
Source evidence
“Our total debt was $48.8 billion at December 31, 2025, and $45.7 billion at December 31, 2024. Our total debt is primarily fixed rate in nature.”

Commercial paper program

Commercial paper programs (US & Europe) with $8.0B aggregate capacity; none outstanding at year-end 2025/2024; average balance $3.0B in 2025

95%
Source evidence
“programs in place in the U.S. and in Europe having an aggregate issuance capacity of $8.0 billion. At December 31, 2025 and 2024, we had no commercial paper outstanding.”

2026 operating cash flow guidance

FY2026 net cash from operating activities expected around $13.5 billion at prevailing exchange rates

95%
Source evidence
“For the full year 2026, we currently expect net cash provided by operating activities of around $13.5 billion at prevailing exchange rates”

Acquisition of Swedish Match and U.S. IQOS rights

Acquired Swedish Match (Nov 2022); full U.S. IQOS rights from April 30, 2024; sold Vectura on Dec 31, 2024

97%
Source evidence
“In November 2022, we acquired Swedish Match AB ("Swedish Match") – a leader in oral nicotine delivery – creating a global smoke-free combination led by the companies’ IQOS and ZYN brands.”

Regulatory risk to smoke-free products

SFP commercialization may be prohibited or restricted by regulators; WHO/FCTC proposals could restrict availability; FDA authorizations subject to strict requirements and not guaranteed to persist

96%
Source evidence
“We cannot predict the extent to which regulators will permit — or continue to permit — the sale and/or marketing of SFPs and regulatory restrictions have, and could further limit, the commercialization of our SFPs.”

Declining tax-paid cigarette consumption

Tax-paid cigarette consumption declining in many markets, threatening funding of the smoke-free transformation

95%
Source evidence
“The decline in the consumption of cigarettes could have a material adverse effect on our revenues, cash flows and profitability, which in turn may have a material adverse effect on our ability to fund our smoke-free transformation.”

Illicit trade / counterfeiting risk

Marlboro most heavily counterfeited international cigarette brand; illicit trade may materially hurt revenues

95%
Source evidence
“We believe that Marlboro is the most heavily counterfeited international cigarette brand, although we cannot quantify the revenues we lose as a result of this activity.”

Currency exchange and capital controls risk

Significant FX translation/transaction exposure to USD; capital controls and devaluations risk in impacted jurisdictions

95%
Source evidence
“Foreign currencies may fluctuate significantly against the U.S. dollar, reducing our net revenues, operating income and EPS.”

Inflation risk

Inflation raises input costs (materials, wages, energy, logistics) and may dampen demand

93%
Source evidence
“Inflationary pressures have and may continue to result in significant increases to our expenses, including direct materials, wages, energy, transportation, and logistics costs.”

Geopolitical exposure incl. Russia/Ukraine and Global Travel Retail

Geopolitical events (incl. Russia-Ukraine) threaten Global Travel Retail volumes, supply chain, and costs

90%
Source evidence
“Any of these developments could cause significant volume declines in our Global Travel Retail business and certain other key markets; disrupt or delay our distribution, manufacturing or supply chain”

Material exposure graph

Smoke-free products (IQOS, ZYN, VEEV)
Demand Driver

FY2025 revenue growth driven by favorable pricing and higher smoke-free products volume/mix, central to PMI's smoke-free transformation strategy.

Relevance 95·Dependency 75·Confidence 95
Source evidence
“favorable volume/mix, driven by higher smoke-free products volume, notwithstanding unfavorable mix and lower volumes for cigarettes”
IQOS heated tobacco units
Revenue Exposure

HTUs were 155.1 billion equivalent units in 2025, +11.0% vs 2024, and HTU international market share rose to 5.8% — the core smoke-free growth engine.

Relevance 95·Dependency 70·Confidence 95
Source evidence
“SFPHTUOral SFPE-vaporCigarettes”
FDA tobacco regulation
Regulatory Exposure

U.S. business success depends on the evolving FDA framework; IQOS and ZYN authorizations could be withdrawn, particularly if youth or non-nicotine user uptake rises.

Relevance 90·Dependency 70·Confidence 94
Source evidence
“there is no guarantee that the products will remain authorized for sale in the United States, or that new versions of IQOS or other ZYN products will receive authorizations, particularly if there is a significant uptake in youth or non-nicotine user initiation”
Russia
Geopolitical Exposure

PMI has ~$4.8B assets in Russia including $2.3B ruble cash and a 23% stake in distributor Megapolis; developments may cause material adverse impact and impairments.

Relevance 90·Dependency 60·Confidence 95
Source evidence
“These developments above have or may have a material adverse impact on our business, results of operations, cash flows and financial position, and may result in impairment charges.”
Marlboro cigarettes
Revenue Exposure

Marlboro accounted for approximately 43% of total 2025 cigarette shipment volume and its cigarette market share rose to 10.7%; cigarette volumes are declining (-1.5% in 2025), concentrating revenue risk.

Relevance 90·Dependency 55·Confidence 97
Source evidence
“led by Marlboro, the world’s best-selling international cigarette, which accounted for approximately 43% of our total 2025 cigarette shipment volume”
U.S. Dollar
Currency Exposure

PMI conducts business primarily in local currencies but reports in USD; FX fluctuations and capital controls materially affect revenues, EPS and cash flows.

Relevance 88·Dependency 80·Confidence 94
Source evidence
“We conduct our business primarily in local currency and, for purposes of financial reporting, the local currency results are translated into U.S. dollars”
Tobacco leaf and non-tobacco raw materials
Supplier Dependency

Cost of sales primarily consists of tobacco leaf, non-tobacco raw materials, labor and manufacturing, shipping, and third-party device electronics manufacturing.

Relevance 80·Dependency 85·Confidence 90
Source evidence
“Our cost of sales consists primarily of: tobacco leaf, non-tobacco raw materials, labor and manufacturing costs; shipping and handling costs; and the cost of devices produced by third-party electronics manufacturing service providers.”
U.S. FDA authorizations (MRTP, PMTA)
Regulatory Exposure

FDA authorized General snus, ZYN nicotine pouches, and IQOS versions — first-ever authorizations in their categories; U.S. commercialization depends on FDA regulatory pathway.

Relevance 80·Dependency 70·Confidence 92
Source evidence
“the U.S. Food and Drug Administration (the "FDA") has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories.”
WHO Framework Convention on Tobacco Control
Regulatory Exposure

WHO/FCTC reports and proposals could lead to restrictions on SFP availability and information access in current or future markets, with potential material adverse effect on financial results and growth.

Relevance 80·Dependency 55·Confidence 90
Source evidence
“A significant factor influencing these developments are reports issued by the World Health Organization (the "WHO”) and Framework Convention on Tobacco Control (the "FCTC")”
Rothmans, Benson & Hedges (Canada)
Legal Exposure

CCAA resolution requires RBH, ITL, JTIM to pay CAD 32.5B global settlement; PMI recorded $2,316M impairment of its RBH equity investment in 2024; allocation unresolved.

Relevance 75·Dependency 60·Confidence 92
Source evidence
“PMI evaluated its investment in RBH for potential impairment and concluded that the estimated fair value of its investment in RBH was lower than its carrying value.”
US Dollar
Currency Exposure

Highly inflationary accounting in Argentina, Egypt, Turkey, Lebanon remeasures monetary items to USD, producing remeasurement losses of $(26)M in 2025.

Relevance 75·Dependency 50·Confidence 90
Source evidence
“monetary assets and liabilities denominated in local currencies are remeasured to the U.S. Dollar at each balance sheet date, with remeasurement gains and losses recognized in consolidated statement of earnings.”
Inflation
Cost Driver

Elevated inflation raises direct materials, wages, energy, transportation, logistics and financing costs and can reduce consumer demand if prices cannot fully offset.

Relevance 72·Dependency 55·Confidence 92
Source evidence
“A sustained period of elevated inflation across the markets in which we operate could result in higher operating and financing costs and lead to reduced demand for our products.”
KT&G
Supplier Dependency

PMI relies exclusively on KT&G smoke-free devices/consumables outside South Korea under a 15-year agreement, and plans joint US PMTA submissions for KT&G heat-not-burn products.

Relevance 70·Dependency 40·Confidence 90
Source evidence
“the partners plan to work on a PMTA submission for review by the U.S. FDA, in accordance with the memorandum.”
Illicit trade and counterfeiting
Competitive Exposure

Counterfeit cigarettes and non-compliant/illicit smoke-free products undermine revenues and the reputation of SFPs; Marlboro most counterfeited brand.

Relevance 68·Dependency 50·Confidence 90
Source evidence
“our revenues may be materially adversely affected by counterfeiting, contraband, cross-border purchases, non-tax-paid volume produced by local manufacturers and other non-compliant or illicit cigarettes or smoke-free products.”
Russia
Legal Exposure

Capital controls and currency constraints in Russia (and Argentina) restrict ability to settle FX imports and pay dividends, increasing devaluation risk.

Relevance 65·Dependency 50·Confidence 85
Source evidence
“In a number of jurisdictions, including Argentina and Russia, we are impacted by various capital controls and/or foreign currency exchange constraints”
Euro
Currency Exposure

Foreign-currency denominated debt and derivatives are subject to FX fluctuation primarily between the Euro and US Dollar, impacting debt levels and deleveraging pace.

Relevance 65·Dependency 45·Confidence 90
Source evidence
“Foreign currency denominated debt and the majority of our $50 billion gross notional amount of derivative financial instruments are subject to foreign currency exchange rates fluctuation, primarily between the Euro and U.S. Dollar”
U.S. FDA PMTA
Regulatory Exposure

KT&G heat-not-burn products selected for US commercialization require FDA PMTA review per the MOU.

Relevance 60·Dependency 45·Confidence 85
Source evidence
“Thereafter, the partners plan to work on a PMTA submission for review by the U.S. FDA, in accordance with the memorandum.”
Altria Group, Inc.
Competitive Exposure

Named competitor; PMI ended the U.S. IQOS commercial relationship with Altria in 2022 and holds full U.S. IQOS rights since April 30, 2024.

Relevance 60·Dependency 25·Confidence 92
Source evidence
“we hold the full rights to commercialize IQOS in the U.S. after reaching an agreement to end our U.S. commercial relationship covering IQOS with Altria Group, Inc. in 2022”
Germany
Tax Exposure

PMI paid ~$0.8B disputed supplemental heated tobacco tax surcharge in Germany, a cash flow and tax exposure for the heated tobacco business there.

Relevance 55·Dependency 35·Confidence 90
Source evidence
“the disputed supplemental tax surcharge on heated tobacco products in Germany of approximately $0.8 billion”
Full company information
Latest profile, trading, valuation, and identifier data stored for PM.
Share price
$211.28
Market cap
$329.30B
Exchange
NYSE
Currency
USD
CEO
Jacek Olczak
Employees
84,900
IPO date
17/03/2008
Beta
0.36
Last dividend
$0.00
Day range
$208.96 – $212.13
52-week range
$146.35 – $214.35
1-day performance
1.56%
1-year performance
44.37%
Current drawdown (1Y)
-1.43%
CIK
0001413329
CUSIP
718172109
ISIN
US7181721090
Created
07/12/2025, 05:47:04
Last update
05/11/2026, 01:06:19

Track Philip Morris International Inc. with an AI analyst

See which prediction-market events move PM, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.